Advertisement
Annovis Bio Says FDA Authorizes Phase 2/3 Trial For Buntanetap In Alzheimer's Disease
(RTTNews) - Annovis Bio, Inc. (ANVS), a late-stage clinical drug platform company, announced Thursday that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).
Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the Company requested approval to further pursue the development of buntanetap in AD.
The FDA approved the Company's development plan, study protocol and authorized the initiation of the Phase 2/3 clinical study of buntanetap in AD.
For More Such Health News, visit rttnews.com
read more
Annovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponed
Drug platform company Annovis Bio, Inc. (ANVS) announced Wednesday a postponement in the Phase III study data release for buntanetap in Parkinson's Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.
RTTNews
|
485日前
Euro Slips On Trump's Tariff Proposal
The euro fell against its major counterparts on Friday, as President Donald Trump proposed tariffs on imports from the European Union starting on June 1.
RTTNews
|
24分前
Swiss Market Ends Weak On Tariff Concerns
After opening on a positive note and staying above the flat line till about an hour past noon, the Switzerland market tumbled on Friday, hurt by U.S. President Donald Trump's threat that imports from the European Union will face 50% tariffs from June 1st.
RTTNews
|
1時16分前
European Stocks Closed Weak On Trump's Fresh Tariff Threat
European stocks closed on a weak note on Friday despite staging a fairly strong recovery past mid afternoon. After staying modestly higher till noon, the major European markets tumbled after U.S. President Donald Trump threatened to impose 50% tariffs on imports from the European Union from June 1st.
RTTNews
|
1時32分前
TSX Recovers After Early Setback; Materials Stocks Move Higher
After a weak start and a subsequent drop to lower levels, the Canadian market recovered well and is down just marginally a little past noon on Friday.
The early setback was due to U.S. President Donald Trump's threat that 50% tariffs will be imposed on imports from the European Union beginning June 1st.
RTTNews
|
2時41分前
U.S. New Home Sales Spike From Downwardly Revised Level In April
The Commerce Department released a report on Friday showing new home sales in the U.S. in the month of April spiked compared to a significantly downwardly revised level in March. The report said new home sales soared by 10.9 percent to an annual rate of 743,000 in April after jumping by 2.6 percent to a downwardly revised rate of 670,000 in March.
RTTNews
|
4時14分前
Germany Logs Stronger Growth On Tariff Threats
The German economy grew at a stronger-than-estimated pace in the first quarter as higher tariff threats by the U.S. administration led to the frontloading of orders for the country's goods, lifting exports and industrial production. Gross domestic product grew 0.4 percent, which was double the initial estimate of 0.2 percent, a detailed report from Destatis revealed on Friday.
RTTNews
|
5時20分前
Bay Street Likely To Open On Negative Note On Tariff Concerns
Canadian shares look headed for a weak start Friday morning as tariff concerns resurfaced after U.S. President Donald Trump threatened 50% tariffs on EU goods from June 1. Weak oil prices could hurt energy stocks and add to market's downside.
RTTNews
|
6時27分前
